Phase IIa trial assessing the efficacy and safety of Enpatoran in patients with dermatomyositis and polymyositis: NEPTUNIA rationale and study design

被引：0
|
作者：
Aggarwal, R. [1 ]
Roy, S. [2 ]
Thommes, G. [3 ]
Weinelt, D. [3 ]
Chitkara, D. [4 ]
Denis, D. [5 ]
机构：
[1] Univ Pittsburgh, Pittsburgh, PA USA
[2] Ares Trading SA, Affiliate Merck KGaA, Eysins, Switzerland
[3] Merck Healthcare KGaA, Darmstadt, Germany
[4] EMD Serono Res & Dev Inst Inc, Affiliate Merck KGaA, Billerica, MA USA
[5] EMD Serono Inc, Affiliate Merck KGaA, Rockland, MA USA
来源：
NEUROMUSCULAR DISORDERS | 2024年 / 43卷
关键词：
D O I：
10.1016/j.nmd.2024.07.393
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
683P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] ROSCO-CF, A SAFETY AND EFFICACY PHASE IIA CLINICAL TRIAL OF SELICICLIB (R-ROSCOVITINE) IN CYSTIC FIBROSIS PATIENTS
    Meijer, L.
    Hery-Arnaud, G.
    Le Berre, R.
    Nowak, E.
    Rault, G.
    Mottier, D.
    PEDIATRIC PULMONOLOGY, 2018, 53 : 224 - 225
  • [42] Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial
    Moriarty, Patrick M.
    Jacobson, Terry A.
    Bruckert, Eric
    Thompson, Paul D.
    Guyton, John R.
    Baccara-Dinet, Marie T.
    Gipe, Daniel
    JOURNAL OF CLINICAL LIPIDOLOGY, 2014, 8 (06) : 554 - 561
  • [43] A PHASE I TRIAL ASSESSING LOMECEL-B INFUSION IN INDIVIDUALS WITH ALZHEIMER'S DISEASE: STUDY DESIGN AND RATIONALE
    Ramdas, Kevin
    Yousefi, Keyvan
    Hitchinson, Ben
    McClain-Moss, Lisa
    Diaz, Liliana
    Baumel, Barry
    Hare, Joshua
    Oliva, Anthony
    INNOVATION IN AGING, 2021, 5 : 647 - 647
  • [44] A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial
    Guimaraes, Helio P.
    de Barros e Silva, Pedro G. M.
    Liporace, Idelzuita L.
    Sampaio, Roney O.
    Tarasoutchi, Flavio
    Paixao, Milena
    Hoffmann-Filho, Conrado R.
    Patriota, Rodrigo
    Leiria, Tiago L. L.
    Lamprea, Diana
    Precoma, Dalton B.
    Atik, Fernando A.
    Silveira, Fabio S.
    Farias, Fabio R.
    Barreto, Diogo O.
    Almeida, Adail P.
    Zilli, Alexandre C.
    de Souza Neto, Joao D.
    Cavalcante, Margaret A.
    Figueira, Fernando A. M. S.
    Junior, Roque A.
    Moises, Valdir A.
    Mesas, Cezar E.
    Ardito, Roberto V.
    Kalil, Paulo S. A.
    Paiva, Maria S. M. O.
    Maldonado, Jaime G. A.
    de Lima, Carlos E. B.
    Vieira, Ricardo D'Oliveira
    Laranjeira, Ligia
    Kojima, Flavia
    Damiani, Lucas
    Nakagawa, Renato H.
    dos Santos, Juliana R. Y.
    Sampaio, Bruna S.
    Campos, Viviane B.
    Saraiva, Jose F. K.
    Fonseca, Francisco H.
    Pinto, Ibraim M.
    Magalhaes, Carlos C.
    Ferreira, Joao F. M.
    Lopes, Renato D.
    Pavanello, Ricardo
    Cavalcanti, Alexandre B.
    Berwanger, Otavio
    AMERICAN HEART JOURNAL, 2021, 231 : 128 - 136
  • [45] Efficacy and Safety of Recombinant Human Prourokinase in Acute Ischemic Stroke: A Phase IIa Randomized Clinical Trial
    Haiqing Song
    Yuan Wang
    Qingfeng Ma
    Huisheng Chen
    Bo Liu
    Yi Yang
    Jianguo Zhu
    Shigang Zhao
    Xiaoping Jin
    Yongqiu Li
    Yanyong Wang
    Runxiu Zhu
    Liandong Zhao
    Junyan Liu
    Qilin Ma
    Yongzhong Lin
    Xiangyang Tian
    Qing Zhang
    Weidong Zhou
    Yongbo Zhang
    Jie Zhou
    Yansong Li
    Zhi Song
    Wuwei Feng
    Rui Liu
    Xunming Ji
    Yuping Wang
    Translational Stroke Research, 2022, 13 : 995 - 1004
  • [46] The OPTICA (OPTImised CTPA In Pregnancy) study: rationale and design of a prospective trial assessing the quality and safety of an optimised CTPA protocol in pregnancy
    Gillespie, C. D.
    Foley, S.
    Ewins, K.
    Rowan, M.
    NiAinle, F.
    MacMahon, P. J.
    THROMBOSIS RESEARCH, 2019, 175 : S9 - S9
  • [47] BASELINE CHARACTERISTICS OF ALL PATIENTS ENROLLED IN A PHASE II CLINICAL TRIAL ASSESSING THE EFFICACY AND SAFETY OF NINTEDANIB IN LYMPHANGIOLEIOMYOMATOSIS
    Cassandro, R.
    Harari, S.
    Caminati, A.
    Elia, D.
    Specchia, C.
    CHEST, 2020, 157 (06) : 160A - 160A
  • [48] A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL OF IVIG 10% IN PATIENTS WITH DERMATOMYOSITIS. THE PRODERM STUDY: RESULTS ON EFFICACY AND SAFETY
    Aggarwal, R.
    Charles-Schoeman, C.
    Schessl, J.
    Bata-Csorgo, Z.
    Dimachkie, M.
    Griger, Z.
    Moiseev, S.
    Oddis, C. V.
    Schiopu, E.
    Vencovsky, J.
    Beckmann, I.
    Levine, T.
    Clodi, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 4 - 5
  • [49] Rationale and Study Design to Assess the Efficacy and Safety of Minocycline in Patients with Moderate to Severe Acute Ischaemic Stroke (EMPHASIS)
    Lu, Yao
    Guan, Ling
    Zhang, Meiyang
    Yang, Qianqian
    Qiu, Baoshan
    Zhou, Dongyang
    Wang, Yicong
    Pan, Yuesong
    Wang, Luyan
    Zhou, Xuejiao
    Qu, Hui
    Liao, Xiaoling
    Liu, Liping
    Zhao, Xingquan
    Bath, Philip M.
    Johnston, S. Claiborne
    Amarenco, Pierre
    Wang, Yongjun
    Wang, Yilong
    STROKE AND VASCULAR NEUROLOGY, 2025,
  • [50] Rationale and design for a study to evaluate the efficacy and safety of PEGylated interferon β-1a in patients with relapsing multiple sclerosis
    Calabresi, P. A.
    Arnold, D.
    Balcer, L.
    Boyko, A.
    Kieseier, B. C.
    Pelletier, J.
    Zhu, Y.
    Davar, G.
    JOURNAL OF NEUROLOGY, 2010, 257 : S148 - S149
12345